US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Zenas BioPharma Inc.

32.32

+1.053.36%

Volume:527.68K

Turnover:16.84M

Market Cap:2.11B

PE:-3.57

High:32.77

Open:31.51

Low:29.88

Close:31.27

52wk High:44.60

52wk Low:13.50

Shares:65.18M

Float Shares:47.02M

Volume Ratio:0.92

T/O Rate:1.12%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-9.0522

EPS(LYR):-8.4448

ROE:-199.04%

ROA:-34.42%

PB:8.53

PE(LYR):-3.83

Loading ...

Overview Company News Filings

Biopharma Firm Xencor's Q2 Revenue Beats on Royalty Revenue, Milestone Payments

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Zenas BioPharma Bear Case Overlooks Obexelimab's Commercial Potential, Wedbush Says

MT Newswires Live

Court Dismisses Securities Lawsuit Against Zenas BioPharma Over IPO Disclosures

Zenas BioPharma (ZBIO) Joins Russell Growth Indexes But Does The Valuation Still Look Pricey

Simply Wall St.

Analysts Offer Insights on Healthcare Companies: Zenas BioPharma, Inc. (ZBIO) and Atai Beckley N.V. (ATAI)

Zenas BioPharma grants 100,000 stock options, 78,075 RSUs to new hires under 2026 inducement plan

Zenas Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Zenas BioPharma to present at H.C. Wainwright Neuro Perspectives Expert Summit

Analysts Are Bullish on Top Healthcare Stocks: Alpha Cognition Inc (ACOG), Zenas BioPharma, Inc. (ZBIO)

A Look At Zenas BioPharma (ZBIO) Valuation After Positive Obexelimab Phase 3 Data And FDA BLA Submission

Simply Wall St.

Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Wednesday Amid Fresh Economic Signals

MT Newswires Live

Zenas BioPharma's Potential Autoimmune Disease Treatment Meets Primary, Secondary Endpoints in Phase 3 Study

MT Newswires Live

Zenas Biopharma Says Phase 3 Indigo Trial Of Obexelimab Meets Primary And All Key Secondary Endpoints

Zenas Biopharma posts corporate presentation on autoimmune disease drug pipeline, led by obexelimab

Zenas BioPharma says Phase 3 INDIGO trial meets primary endpoint for obexelimab in IgG4-related disease

Zenas Biopharma Announces Data From the Registrational Phase 3 Indigo Trial of Obexelimab in Immunoglobulin G4-Related Disease (Igg4-Rd), Simultaneously Presented at the Eular 2026 Congress and Published in the New England Journal of Medicine

THOMSON REUTERS

Zenas Biopharma - Obexelimab Significantly Lowers Glucocorticoid Use and Toxicities in Indigo Trial

THOMSON REUTERS

Zenas Biopharma - Phase 3 Indigo Trial of Obexelimab Meets Primary and All Key Secondary Endpoints

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigerplaytime.com/stock/ZBIO/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ZBIO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ZBIO\",,,,,undefined,":{"symbol":"ZBIO","market":"US","secType":"STK","nameCN":"Zenas BioPharma Inc.","latestPrice":32.32,"timestamp":1788206400000,"preClose":31.27,"halted":0,"volume":527681,"delay":0,"changeRate":0.03357850975375762,"floatShares":47024692,"shares":65176700,"eps":-9.052203,"marketStatus":"Pre-Mkt","change":1.05,"latestTime":"09-01 06:01:41 EDT","open":31.51,"high":32.77,"low":29.88,"amount":16837732.925244,"amplitude":0.092421,"askPrice":43.42,"askSize":100,"bidPrice":25.61,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-9.052203,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1788269400000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1726200000000,"exchange":"NASDAQ","adjPreClose":32.32,"sharesOutstanding":249967,"nav":10.0592,"aum":2514468.0464,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":32.32,"preClose":32.32,"latestTime":"19:30 EDT","volume":30954,"amount":1000426.078168,"timestamp":1788219002875,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.9208591086888067,"impliedVol":0.5896,"impliedVolPercentile":0.0797},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ZBIO\",,,,,undefined,":{"symbol":"ZBIO","floatShares":47024692,"roa":"-34.42%","roe":"-199.04%","lyrEps":-8.444814,"volumeRatio":0.9208591086888067,"shares":65176700,"dividePrice":0,"high":32.77,"amplitude":0.092421,"preClose":31.27,"low":29.88,"week52Low":13.5,"pbRate":"8.53","psRate":"2106.51","week52High":44.6,"institutionHeld":0,"latestPrice":32.32,"eps":-9.052203,"divideRate":0,"volume":527681,"delay":0,"ttmEps":-9.052203,"open":31.51,"prevYearClose":36.31,"prevWeekClose":31.27,"prevMonthClose":32.32,"prevQuarterClose":25.38,"fiveDayClose":31.65,"twentyDayClose":31.13,"sixtyDayClose":18.38},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ZBIO\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-13","symbol":"ZBIO","fiscalQuarterEnding":"2026/06","expectedEps":-0.89,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1786593600000,"reportTimeType":"pre","actualEps":-1.77},{"market":"US","date":"2026-05-13","symbol":"ZBIO","fiscalQuarterEnding":"2026/03","expectedEps":-1.37,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1778644800000,"reportTimeType":"pre","actualEps":-1.46},{"market":"US","date":"2026-03-16","symbol":"ZBIO","fiscalQuarterEnding":"2025/12","expectedEps":-1.22,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1773633600000,"reportTimeType":"pre","actualEps":-4.54},{"market":"US","date":"2025-11-12","symbol":"ZBIO","fiscalQuarterEnding":"2025/09","expectedEps":-0.87,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1762923600000,"reportTimeType":"pre","actualEps":-1.22},{"market":"US","date":"2025-08-12","symbol":"ZBIO","fiscalQuarterEnding":"2025/06","expectedEps":-1.02,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1754971200000,"reportTimeType":"pre","actualEps":-1.25}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ZBIO\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ZBIO\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.625,"buy":0.25,"hold":0.125,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.625,"analysts":8,"updateTime":1767931200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ZBIO\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ZBIO","date":"2026-08-31","current":-3.570402,"percent":0.430612,"low":-19.592941,"twenty":-7.357957,"median":-3.88256,"eighty":-2.619118,"high":-1.802568,"avg":-5.29957,"sd":3.710357,"marketCap":2038076128},"quantilePoints":[{"date":"2024-09-13","current":-8.364044,"twenty":-11.189626,"median":-10.130033,"eighty":-9.07044,"marketCap":457989962},{"date":"2024-09-20","current":-12.731934,"twenty":-12.968841,"median":-12.731934,"eighty":-9.523082,"marketCap":697162515},{"date":"2024-09-27","current":-12.564791,"twenty":-13.484804,"median":-12.909978,"eighty":-12.029776,"marketCap":688010267},{"date":"2024-10-04","current":-14.275075,"twenty":-13.747873,"median":-12.811872,"eighty":-12.31335,"marketCap":781660299},{"date":"2024-10-11","current":-13.008553,"twenty":-13.941177,"median":-13.027627,"eighty":-12.397648,"marketCap":712309358},{"date":"2024-10-18","current":-16.373229,"twenty":-14.273549,"median":-13.29848,"eighty":-12.477586,"marketCap":896548905},{"date":"2024-10-25","current":-17.845752,"twenty":-15.022781,"median":-13.503182,"eighty":-12.59822,"marketCap":977179818},{"date":"2024-10-31","current":-16.022265,"twenty":-16.022265,"median":-13.891034,"eighty":-12.731934,"marketCap":877331175},{"date":"2024-11-08","current":-15.961228,"twenty":-15.961228,"median":-14.267446,"eighty":-12.811872,"marketCap":873988961},{"date":"2024-11-15","current":-6.06727,"twenty":-16.022265,"median":-14.202594,"eighty":-12.564791,"marketCap":782495852},{"date":"2024-11-22","current":-3.382919,"twenty":-15.961228,"median":-13.807463,"eighty":-11.896022,"marketCap":436298426},{"date":"2024-11-29","current":-3.729636,"twenty":-15.955124,"median":-13.496851,"eighty":-6.578437,"marketCap":481014835},{"date":"2024-12-06","current":-3.402361,"twenty":-15.898664,"median":-13.178717,"eighty":-4.851473,"marketCap":438805888},{"date":"2024-12-13","current":-2.997318,"twenty":-15.744546,"median":-13.008553,"eighty":-3.729636,"marketCap":386567092},{"date":"2024-12-20","current":-3.162575,"twenty":-15.636205,"median":-12.771903,"eighty":-3.606503,"marketCap":407880521},{"date":"2024-12-27","current":-3.256545,"twenty":-15.585849,"median":-12.510288,"eighty":-3.394584,"marketCap":419999921},{"date":"2025-01-03","current":-2.91955,"twenty":-15.427152,"median":-12.339512,"eighty":-3.24488,"marketCap":376537243},{"date":"2025-01-10","current":-3.007039,"twenty":-15.189107,"median":-10.412935,"eighty":-3.188498,"marketCap":387820823},{"date":"2025-01-17","current":-2.520987,"twenty":-15.022781,"median":-6.676265,"eighty":-3.159983,"marketCap":325134267},{"date":"2025-01-24","current":-2.715408,"twenty":-14.870188,"median":-6.06727,"eighty":-3.071846,"marketCap":350208890},{"date":"2025-01-31","current":-2.469142,"twenty":-14.351372,"median":-4.794107,"eighty":-2.968155,"marketCap":318447701},{"date":"2025-02-07","current":-2.54367,"twenty":-14.313224,"median":-3.888412,"eighty":-2.841781,"marketCap":328059640},{"date":"2025-02-14","current":-2.313605,"twenty":-14.275075,"median":-3.716674,"eighty":-2.653842,"marketCap":298388004},{"date":"2025-02-21","current":-2.530708,"twenty":-14.268972,"median":-3.643766,"eighty":-2.622086,"marketCap":326387998},{"date":"2025-02-28","current":-2.141867,"twenty":-14.163683,"median":-3.476889,"eighty":-2.54367,"marketCap":276238754},{"date":"2025-03-07","current":-2.35573,"twenty":-14.007233,"median":-3.332693,"eighty":-2.517747,"marketCap":303820838},{"date":"2025-03-14","current":-2.324434,"twenty":-13.840892,"median":-3.246824,"eighty":-2.465902,"marketCap":364908203},{"date":"2025-03-21","current":-2.26852,"twenty":-13.569102,"median":-3.188498,"eighty":-2.360915,"marketCap":356130342},{"date":"2025-03-28","current":-2.138053,"twenty":-13.499383,"median":-3.165816,"eighty":-2.351842,"marketCap":335648668},{"date":"2025-04-04","current":-2.076814,"twenty":-13.408148,"median":-3.159335,"eighty":-2.284767,"marketCap":326034820},{"date":"2025-04-11","current":-1.80523,"twenty":-13.315978,"median":-3.071846,"eighty":-2.26652,"marketCap":283399498},{"date":"2025-04-17","current":-2.21793,"twenty":-13.154764,"median":-2.997318,"eighty":-2.257224,"marketCap":348188468},{"date":"2025-04-25","current":-2.657256,"twenty":-13.051602,"median":-2.943853,"eighty":-2.261324,"marketCap":417157373},{"date":"2025-05-02","current":-3.077944,"twenty":-13.023813,"median":-2.968155,"eighty":-2.26639,"marketCap":483200324},{"date":"2025-05-09","current":-2.4756,"twenty":-13.008271,"median":-2.943853,"eighty":-2.269325,"marketCap":388639550},{"date":"2025-05-16","current":-2.503456,"twenty":-12.890356,"median":-2.890387,"eighty":-2.270833,"marketCap":407464932},{"date":"2025-05-23","current":-2.942974,"twenty":-12.763909,"median":-2.866084,"eighty":-2.272453,"marketCap":479001383},{"date":"2025-05-30","current":-2.570283,"twenty":-12.665077,"median":-2.835832,"eighty":-2.278934,"marketCap":418341820},{"date":"2025-06-06","current":-2.470042,"twenty":-12.521189,"median":-2.721889,"eighty":-2.297829,"marketCap":402026489},{"date":"2025-06-13","current":-2.90956,"twenty":-12.426717,"median":-2.835832,"eighty":-2.31327,"marketCap":473562940},{"date":"2025-06-20","current":-2.392933,"twenty":-12.365673,"median":-2.76689,"eighty":-2.315238,"marketCap":389476234},{"date":"2025-06-27","current":-2.608837,"twenty":-12.215932,"median":-2.714219,"eighty":-2.322158,"marketCap":424616947},{"date":"2025-07-03","current":-2.577994,"twenty":-11.896022,"median":-2.691086,"eighty":-2.323707,"marketCap":419596845},{"date":"2025-07-11","current":-3.102331,"twenty":-8.929847,"median":-2.679496,"eighty":-2.324434,"marketCap":504938576},{"date":"2025-07-18","current":-3.387633,"twenty":-8.364044,"median":-2.699206,"eighty":-2.336288,"marketCap":551374518},{"date":"2025-07-25","current":-4.194702,"twenty":-6.676265,"median":-2.718649,"eighty":-2.349239,"marketCap":682733850},{"date":"2025-08-01","current":-4.037914,"twenty":-6.187126,"median":-2.829882,"eighty":-2.35573,"marketCap":657214999},{"date":"2025-08-08","current":-3.804019,"twenty":-6.06727,"median":-2.865865,"eighty":-2.35573,"marketCap":619145893},{"date":"2025-08-15","current":-3.987237,"twenty":-5.542498,"median":-2.90956,"eighty":-2.36209,"marketCap":705768845},{"date":"2025-08-22","current":-4.02768,"twenty":-4.889717,"median":-2.928692,"eighty":-2.362211,"marketCap":712927599},{"date":"2025-08-29","current":-3.868286,"twenty":-4.698498,"median":-2.950685,"eighty":-2.372371,"marketCap":684713689},{"date":"2025-09-05","current":-4.039575,"twenty":-4.396216,"median":-2.982091,"eighty":-2.374493,"marketCap":715033114},{"date":"2025-09-12","current":-4.798483,"twenty":-4.881439,"median":-2.99503,"eighty":-2.389351,"marketCap":849365013},{"date":"2025-09-19","current":-4.629572,"twenty":-4.881439,"median":-3.063777,"eighty":-2.399463,"marketCap":819466690},{"date":"2025-09-26","current":-4.429735,"twenty":-4.835595,"median":-3.074895,"eighty":-2.402603,"marketCap":784094028},{"date":"2025-10-03","current":-4.984046,"twenty":-4.911724,"median":-3.083269,"eighty":-2.409912,"marketCap":882211057},{"date":"2025-10-10","current":-6.604159,"twenty":-5.180553,"median":-3.135974,"eighty":-2.413574,"marketCap":1168982288},{"date":"2025-10-17","current":-5.759607,"twenty":-5.320916,"median":-3.162575,"eighty":-2.420654,"marketCap":1019490677},{"date":"2025-10-24","current":-5.949928,"twenty":-5.76722,"median":-3.174048,"eighty":-2.42495,"marketCap":1053178928},{"date":"2025-10-31","current":-9.035303,"twenty":-6.083769,"median":-3.188498,"eighty":-2.432369,"marketCap":1599311910},{"date":"2025-11-07","current":-9.81546,"twenty":-6.198298,"median":-3.245204,"eighty":-2.444339,"marketCap":1737405107},{"date":"2025-11-14","current":-10.08009,"twenty":-6.457611,"median":-3.282468,"eighty":-2.446909,"marketCap":1914199059},{"date":"2025-11-21","current":-9.848299,"twenty":-7.258864,"median":-3.371139,"eighty":-2.451734,"marketCap":1870182143},{"date":"2025-11-28","current":-10.976161,"twenty":-8.972029,"median":-3.394997,"eighty":-2.453948,"marketCap":2084362015},{"date":"2025-12-05","current":-10.772637,"twenty":-9.459248,"median":-3.515773,"eighty":-2.459247,"marketCap":2045713016},{"date":"2025-12-12","current":-11.366249,"twenty":-9.83041,"median":-3.643766,"eighty":-2.466418,"marketCap":2158439264},{"date":"2025-12-19","current":-9.913314,"twenty":-9.980024,"median":-3.678075,"eighty":-2.469682,"marketCap":1882528351},{"date":"2025-12-26","current":-12.202958,"twenty":-10.134363,"median":-3.729636,"eighty":-2.472265,"marketCap":2317329596},{"date":"2026-01-02","current":-10.263827,"twenty":-10.232168,"median":-3.760324,"eighty":-2.476253,"marketCap":1949090517},{"date":"2026-01-09","current":-4.638651,"twenty":-10.207521,"median":-3.79333,"eighty":-2.479511,"marketCap":880875114},{"date":"2026-01-16","current":-5.633657,"twenty":-10.159019,"median":-3.831007,"eighty":-2.483289,"marketCap":1069825778},{"date":"2026-01-23","current":-5.766513,"twenty":-10.142278,"median":-3.88256,"eighty":-2.488034,"marketCap":1095054986},{"date":"2026-01-30","current":-5.902195,"twenty":-10.122491,"median":-3.950232,"eighty":-2.490604,"marketCap":1120820986},{"date":"2026-02-06","current":-5.938943,"twenty":-10.119664,"median":-3.975342,"eighty":-2.498305,"marketCap":1127799277},{"date":"2026-02-13","current":-7.380571,"twenty":-10.08009,"median":-4.008147,"eighty":-2.503456,"marketCap":1401563024},{"date":"2026-02-20","current":-7.637803,"twenty":-9.946669,"median":-4.026371,"eighty":-2.50452,"marketCap":1450411065},{"date":"2026-02-27","current":-7.451239,"twenty":-9.897484,"median":-4.035344,"eighty":-2.514003,"marketCap":1414982815},{"date":"2026-03-06","current":-7.140299,"twenty":-9.857345,"median":-4.041954,"eighty":-2.520051,"marketCap":1355935733},{"date":"2026-03-13","current":-6.925469,"twenty":-9.824447,"median":-4.068124,"eighty":-2.528764,"marketCap":1315139567},{"date":"2026-03-20","current":-3.549457,"twenty":-9.816065,"median":-4.041954,"eighty":-2.535893,"marketCap":1340761298},{"date":"2026-03-27","current":-3.365681,"twenty":-9.764845,"median":-4.035344,"eighty":-2.542374,"marketCap":1271342335},{"date":"2026-04-02","current":-3.206266,"twenty":-9.752191,"median":-4.02768,"eighty":-2.54367,"marketCap":1211125146},{"date":"2026-04-10","current":-3.351146,"twenty":-9.585134,"median":-4.008147,"eighty":-2.555011,"marketCap":1265851823},{"date":"2026-04-17","current":-3.426736,"twenty":-9.459248,"median":-3.975342,"eighty":-2.562572,"marketCap":1294404871},{"date":"2026-04-24","current":-2.91178,"twenty":-9.318941,"median":-3.950232,"eighty":-2.56484,"marketCap":1099887227},{"date":"2026-05-01","current":-3.042488,"twenty":-9.220114,"median":-3.88256,"eighty":-2.568711,"marketCap":1149260207},{"date":"2026-05-08","current":-3.034614,"twenty":-9.118797,"median":-3.818719,"eighty":-2.573367,"marketCap":1146285931},{"date":"2026-05-15","current":-2.806581,"twenty":-9.04377,"median":-3.782641,"eighty":-2.576966,"marketCap":1193220825},{"date":"2026-05-22","current":-2.946168,"twenty":-8.972029,"median":-3.74498,"eighty":-2.576966,"marketCap":1252566199},{"date":"2026-05-29","current":-2.756092,"twenty":-8.703526,"median":-3.716674,"eighty":-2.577994,"marketCap":1171755477},{"date":"2026-06-05","current":-2.729363,"twenty":-8.073548,"median":-3.672934,"eighty":-2.577994,"marketCap":1160391469},{"date":"2026-06-12","current":-2.637295,"twenty":-7.609535,"median":-3.597675,"eighty":-2.580331,"marketCap":1121248775},{"date":"2026-06-18","current":-2.759062,"twenty":-7.566764,"median":-3.544789,"eighty":-2.584211,"marketCap":1173018144},{"date":"2026-06-26","current":-3.663405,"twenty":-7.560564,"median":-3.528998,"eighty":-2.58741,"marketCap":1557500410},{"date":"2026-07-02","current":-4.157898,"twenty":-7.541694,"median":-3.549457,"eighty":-2.594231,"marketCap":1767734556},{"date":"2026-07-10","current":-4.370248,"twenty":-7.462546,"median":-3.643766,"eighty":-2.595516,"marketCap":1858015285},{"date":"2026-07-17","current":-4.193537,"twenty":-7.451239,"median":-3.672934,"eighty":-2.596017,"marketCap":1782886566},{"date":"2026-07-24","current":-4.601902,"twenty":-7.448412,"median":-3.716674,"eighty":-2.598756,"marketCap":1956503353},{"date":"2026-07-31","current":-4.791978,"twenty":-7.400923,"median":-3.74498,"eighty":-2.598756,"marketCap":2037314075},{"date":"2026-08-07","current":-4.777128,"twenty":-7.389051,"median":-3.770746,"eighty":-2.606821,"marketCap":2031000738},{"date":"2026-08-14","current":-3.929032,"twenty":-7.382267,"median":-3.79905,"eighty":-2.610296,"marketCap":1903160311},{"date":"2026-08-21","current":-4.254657,"twenty":-7.371525,"median":-3.831007,"eighty":-2.614149,"marketCap":2060887981},{"date":"2026-08-28","current":-4.389213,"twenty":-7.360218,"median":-3.875423,"eighty":-2.618299,"marketCap":2126064704},{"date":"2026-08-31","current":-4.207563,"twenty":-7.357957,"median":-3.88256,"eighty":-2.619118,"marketCap":2038076128}],"updateTime":1788256901487},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ZBIO\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2657520170","title":"Biopharma Firm Xencor's Q2 Revenue Beats on Royalty Revenue, Milestone Payments","url":"https://stock-news.laohu8.com/highlight/detail?id=2657520170","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657520170?lang=en_us&edition=fundamental","pubTime":"2026-08-06 04:13","pubTimestamp":1785960830,"startTime":"0","endTime":"0","summary":"Biopharma firm Xencor's Q2 revenue beats on royalty revenue, milestone paymentsOverviewUS biopharma firm's Q2 revenue rose, beating analyst expectationsCompany posted narrower net loss of $21.7 mln, o","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nL1N4421AV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XNCR","ZBIO","RPRX","IMRX","BK4563","BK4007","IHE","PBE","BK4139","BK4539","KYMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652280744","title":"Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2652280744","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652280744?lang=en_us&edition=fundamental","pubTime":"2026-07-18 04:15","pubTimestamp":1784319300,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., July  17, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/17/3329284/0/en/Zenas-BioPharma-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LCLG","ZBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652881702","title":"Zenas BioPharma Bear Case Overlooks Obexelimab's Commercial Potential, Wedbush Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2652881702","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652881702?lang=en_us&edition=fundamental","pubTime":"2026-07-17 20:13","pubTimestamp":1784290436,"startTime":"0","endTime":"0","summary":"Zenas BioPharma  remains undervalued, as investor concerns over its phase 3 INDIGO trial for obexelimab place too much emphasis on comparisons with Amgen's Uplizna while overlooking factors that could support broader market adoption, Wedbush said in a Friday note.The brokerage said the addressable market for obexelimab could be about 75% larger than previously estimated, adding that the drug's favorable safety profile, lower steroid use, reduced infection risk and lower treatment costs compared with Uplizna could support broader adoption.Wedbush said several upcoming catalysts over the next 12 months, including data from the INDIGO vaccine sub-study, topline phase 2 SunStone trial results in systemic lupus erythematosus, and healthy volunteer data for oral IL-17 inhibitor ZB021, could renew investor interest.Updates on Uplizna sales and growth in the IgG4-related disease market could further support obexelimab's commercial outlook, with its safety profile and potential physician and pa","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","ZBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650915611","title":"Court Dismisses Securities Lawsuit Against Zenas BioPharma Over IPO Disclosures","url":"https://stock-news.laohu8.com/highlight/detail?id=2650915611","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650915611?lang=en_us&edition=fundamental","pubTime":"2026-07-09 03:59","pubTimestamp":1783540789,"startTime":"0","endTime":"0","summary":"A federal judge in Massachusetts has dismissed a securities lawsuit against Zenas BioPharma, Inc. (NASDAQ: ZBIO), ruling that the clinical-stage bi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/class-action/court-dismisses-securities-lawsuit-against-zenas-biopharma-over-ipo-disclosures?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/class-action/court-dismisses-securities-lawsuit-against-zenas-biopharma-over-ipo-disclosures?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KCE","GPIQ","QLD","QQQM","QQQJ","QYLG","BK4139","QQQY","BK4127","QQQE","TQQY","QDTE","ONEQ","FRHC","PSQ","NDX","QQQ","SQQQ","NQmain","IPOS",".IXIC","TECS","TQQQ","MNQmain","JEPQ","NVIW.SI","QQQA","IYW","FTEC","ZBIO","QID"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649610879","title":"Zenas BioPharma (ZBIO) Joins Russell Growth Indexes But Does The Valuation Still Look Pricey","url":"https://stock-news.laohu8.com/highlight/detail?id=2649610879","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649610879?lang=en_us&edition=fundamental","pubTime":"2026-07-08 16:28","pubTimestamp":1783499327,"startTime":"0","endTime":"0","summary":"Index reshuffle puts Zenas BioPharma in growth-focused benchmarks\nZenas BioPharma (ZBIO) has been reclassified across several Russell indexes, moving into multiple growth benchmarks while being removed from various value indexes. This shift can affect investor flows through index fund rebalancing.\nSee our latest analysis for Zenas BioPharma.\nThe index reshuffle comes after a sharp shift in momentum for Zenas BioPharma, with the stock posting a 1 month share price return of 58.44% and a 1 year...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-zbio/zenas-biopharma/news/zenas-biopharma-zbio-joins-russell-growth-indexes-but-does-t","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-zbio/zenas-biopharma/news/zenas-biopharma-zbio-joins-russell-growth-indexes-but-does-t","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","ZBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646644513","title":"Analysts Offer Insights on Healthcare Companies: Zenas BioPharma, Inc. (ZBIO) and Atai Beckley N.V. (ATAI)","url":"https://stock-news.laohu8.com/highlight/detail?id=2646644513","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646644513?lang=en_us&edition=fundamental","pubTime":"2026-06-27 01:20","pubTimestamp":1782494414,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Zenas BioPharma, Inc. (ZBIO) and Atai Beckley N.V. (...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-zenas-biopharma-inc-zbio-and-atai-beckley-n-v-atai-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-zenas-biopharma-inc-zbio-and-atai-beckley-n-v-atai-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ATAI","HCSG","LABU","LU0029874061.USD","LU0128526141.USD","XLV","BK4139","BK4585","XBI","ZBIO","BK4137","BK4007","BK4581","BK4588","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644297997","title":"Zenas BioPharma grants 100,000 stock options, 78,075 RSUs to new hires under 2026 inducement plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2644297997","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644297997?lang=en_us&edition=fundamental","pubTime":"2026-06-18 04:15","pubTimestamp":1781727324,"startTime":"0","endTime":"0","summary":"Zenas BioPharma granted inducement equity awards dated June 15, 2026 to newly hired employees: stock options for 100,000 shares, RSUs for 78,075 shares.Options carry a 10-year term, $18.71 exercise price, vesting over four years with 25% after one year, then monthly installments.RSUs vest in four equal tranches on June 15 of 2027 through 2030, subject to continued service.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nNDL2XCDyW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","ZBIO","IE00BKPKM429.USD","BK4112","IE00B3QW5Z07.USD","BK4588","IE00BGHQF748.EUR","LU2095319765.USD","LU2210150020.SGD","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","IE00B64PRP62.GBP","NDAQ","IE00BN0W2W23.USD","SG9999014039.USD","LU0314104364.USD","SG9999014013.SGD","BK4139","SG9999014021.USD","SG9999014005.SGD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644172922","title":"Zenas Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2644172922","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644172922?lang=en_us&edition=fundamental","pubTime":"2026-06-18 04:15","pubTimestamp":1781727300,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nTUAJ4RVD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ZBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644942721","title":"Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2644942721","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644942721?lang=en_us&edition=fundamental","pubTime":"2026-06-18 04:15","pubTimestamp":1781727300,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., June  17, 2026  (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/17/3313812/0/en/Zenas-BioPharma-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642023120","title":"Zenas BioPharma to present at H.C. Wainwright Neuro Perspectives Expert Summit","url":"https://stock-news.laohu8.com/highlight/detail?id=2642023120","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642023120?lang=en_us&edition=fundamental","pubTime":"2026-06-12 04:16","pubTimestamp":1781208970,"startTime":"0","endTime":"0","summary":"Zenas BioPharma management to present at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit on June 15, 2026.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260611:nNDL2gc40m:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014013.SGD","IE00BN0W2T93.GBP","SG9999014005.SGD","SG9999014021.USD","IE00B64PRP62.GBP","BK4139","IE00B3QW5Z07.USD","SG9999014039.USD","LU0314104364.USD","IE00BN0W2W23.USD","ZBIO","IE00BGHQF748.EUR","BK4588","BK4112","IE00BN0W2V16.EUR","NDAQ","BK4585","LU2210150020.SGD","LU2095319765.USD","IE00BKPKM429.USD","LU2210149790.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642280342","title":"Analysts Are Bullish on Top Healthcare Stocks: Alpha Cognition Inc (ACOG), Zenas BioPharma, Inc. (ZBIO)","url":"https://stock-news.laohu8.com/highlight/detail?id=2642280342","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642280342?lang=en_us&edition=fundamental","pubTime":"2026-06-11 21:40","pubTimestamp":1781185212,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Alpha Cognition Inc (ACOG), Zenas BioPharma, Inc. (Z...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-alpha-cognition-inc-acog-zenas-biopharma-inc-zbio-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-alpha-cognition-inc-acog-zenas-biopharma-inc-zbio-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ACOG","ZBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641480868","title":"A Look At Zenas BioPharma (ZBIO) Valuation After Positive Obexelimab Phase 3 Data And FDA BLA Submission","url":"https://stock-news.laohu8.com/highlight/detail?id=2641480868","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641480868?lang=en_us&edition=fundamental","pubTime":"2026-06-08 21:28","pubTimestamp":1780925285,"startTime":"0","endTime":"0","summary":"Clinical data and regulatory milestones in focus\nZenas BioPharma (ZBIO) stock is drawing attention after the company reported detailed Phase 3 INDIGO data for obexelimab in IgG4-Related Disease and advanced a Biologics License Application with the FDA.\nSee our latest analysis for Zenas BioPharma.\nDespite the positive INDIGO data and recent Biologics License Application filing, Zenas BioPharma's share price has come under pressure, with the stock down 11.05% over 30 days and 49.36% year to...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-zbio/zenas-biopharma/news/a-look-at-zenas-biopharma-zbio-valuation-after-positive-obex","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-zbio/zenas-biopharma/news/a-look-at-zenas-biopharma-zbio-valuation-after-positive-obex","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ZBIO","BK4588","LABU","BK4139","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640021949","title":"Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Wednesday Amid Fresh Economic Signals","url":"https://stock-news.laohu8.com/highlight/detail?id=2640021949","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640021949?lang=en_us&edition=fundamental","pubTime":"2026-06-03 21:10","pubTimestamp":1780492243,"startTime":"0","endTime":"0","summary":"The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.2% and the actively traded Invesco QQQ Trust (QQQ) advanced 0.5% in Wednesday's premarket activity, as markets traded mixe","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["FDN","RACE","CXM.AU","EEM","VHT.AU","BITO","XLK","XLI","EQR","XLV","IYK","XLE","GLD","SPY.AU","FAZ","BX","QQQ","USO",".IXIC","IYW","CXM","IWM","PMR","BP","IVV","VIS","SPY","IYJ","TE","XLP","UNG","EETH","RTH","XSD","IGM","IBB","FAS","IGV","RTH.AU","BETH","XLY","XLF","IYH","VDC","IYE","XRT","ZBIO","SOXX","VHT","SLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640553977","title":"Zenas BioPharma's Potential Autoimmune Disease Treatment Meets Primary, Secondary Endpoints in Phase 3 Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2640553977","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640553977?lang=en_us&edition=fundamental","pubTime":"2026-06-03 16:41","pubTimestamp":1780476109,"startTime":"0","endTime":"0","summary":"Zenas BioPharma's (ZBIO) obexelimab met all primary and secondary endpoints with \"statistically significant\" results in a phase 3 study in patients with immunoglobulin G4-related disease, the company ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","ZBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640606921","title":"Zenas Biopharma Says Phase 3 Indigo Trial Of Obexelimab Meets Primary And All Key Secondary Endpoints","url":"https://stock-news.laohu8.com/highlight/detail?id=2640606921","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640606921?lang=en_us&edition=fundamental","pubTime":"2026-06-03 07:18","pubTimestamp":1780442336,"startTime":"0","endTime":"0","summary":"June 2 (Reuters) - Zenas Biopharma Inc ::*ZENAS BIOPHARMA ANNOUNCES DATA FROM THE REGISTRATIONAL PHASE 3 INDIGO TRIAL OF OBEXELIMAB IN IMMUNOGLOBULIN G4-RELATED DISEASE (IGG4-RD), SIMULTANEOUSLY PRESE","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nRSD3qpDrF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ZBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640921667","title":"Zenas Biopharma posts corporate presentation on autoimmune disease drug pipeline, led by obexelimab","url":"https://stock-news.laohu8.com/highlight/detail?id=2640921667","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640921667?lang=en_us&edition=fundamental","pubTime":"2026-06-03 07:12","pubTimestamp":1780441950,"startTime":"0","endTime":"0","summary":"Zenas Biopharma outlined plans to transition to a commercial-stage autoimmune company, citing cash runway into 2029.INDIGO Phase 3 IgG4-RD met the primary endpoint; flare risk reduced 56% vs placebo, HR 0.41; 73% flare-free at week 52.Pipeline focus spans obexelimab, orelabrutinib, ZB021; clinical catalysts include SunStone Phase 2 SLE topline in Q4 2026.Zenas targets potential approvals for three franchise molecules across five I&I indications by 2031; markets estimated at more than $50 billion.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zenas Biopharma Inc. published the original content used to generate this news brief on June 02, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nNDL5LBKvv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640921521","title":"Zenas BioPharma says Phase 3 INDIGO trial meets primary endpoint for obexelimab in IgG4-related disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2640921521","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640921521?lang=en_us&edition=fundamental","pubTime":"2026-06-03 07:05","pubTimestamp":1780441518,"startTime":"0","endTime":"0","summary":"Zenas BioPharma reported additional positive Phase 3 INDIGO results for obexelimab in IgG4-related disease, presented at EULAR 2026 and published in NEJM.The registrational study met its primary endpoint and key secondary endpoints, showing lower disease activity and fewer flares versus placebo.Obexelimab reduced overall steroid use, supporting a steroid-sparing profile with fewer glucocorticoid-related toxicities.Safety was comparable to placebo, strengthening the drug’s risk-benefit profile ahead of potential commercialization.A Biologics License Application for IgG4-related disease was submitted to the FDA in May, setting up a near-term regulatory catalyst.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nNDL2lKBtB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","SG9999014021.USD","IE00BN0W2W23.USD","BK4112","LU2095319765.USD","SG9999014005.SGD","IE00BN0W2V16.EUR","SG9999014013.SGD","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","IE00BN0W2T93.GBP","LU2210150020.SGD","IE00BGHQF748.EUR","IE00BKPKM429.USD","BK4139","BK4588","LU2210149790.SGD","BK4585","ZBIO","NDAQ","SG9999014039.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640921597","title":"Zenas Biopharma Announces Data From the Registrational Phase 3 Indigo Trial of Obexelimab in Immunoglobulin G4-Related Disease (Igg4-Rd), Simultaneously Presented at the Eular 2026 Congress and Published in the New England Journal of Medicine","url":"https://stock-news.laohu8.com/highlight/detail?id=2640921597","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640921597?lang=en_us&edition=fundamental","pubTime":"2026-06-03 07:05","pubTimestamp":1780441500,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nTUA6N8J1T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ZBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640921549","title":"Zenas Biopharma - Obexelimab Significantly Lowers Glucocorticoid Use and Toxicities in Indigo Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2640921549","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640921549?lang=en_us&edition=fundamental","pubTime":"2026-06-03 07:05","pubTimestamp":1780441500,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nTUA6N8J1T:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ZBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640921511","title":"Zenas Biopharma - Phase 3 Indigo Trial of Obexelimab Meets Primary and All Key Secondary Endpoints","url":"https://stock-news.laohu8.com/highlight/detail?id=2640921511","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640921511?lang=en_us&edition=fundamental","pubTime":"2026-06-03 07:05","pubTimestamp":1780441500,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nTUA6N8J1T:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ZBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":2,"totalSize":111,"code":"91000000","status":"200"}]}}